Floatz logo

Valemetostat

Clear Cell Endometrial Carcinoma

Gustave Roussy, Cancer Campus, Grand ParisSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Clear Cell Endometrial Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Floor Backes, MD
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Metformin
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC

View all 16 →

Same molecule, other indications

Valemetostat is also rated in:

adult T-cell leukemia/lymphomaDormant
B
Indicative ·
57 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →